Therapeutic drug monitoring of linezolid and exploring optimal regimens and a toxicity-related nomogram in elderly patients: a multicentre, prospective, non-interventional study
Journal of Antimicrobial Chemotherapy · 01.08.2024 · 79 (8) · 1938-1950
DOI: 10.1093/jac/dkae188 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 14.06.2024. Verfasst von Tingting Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA …. Hauptthemen laut MEDLINE: Linezolid, Nomograms, Drug Monitoring, Anti-Bacterial Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, National Clinical Research Center Projects for Geriatric Diseases, Special Project for Military Healthcare Scientific Research.
Abstract (Originalsprache)
Background
The concentrations of linezolid, its optimal regimen and the associated side effects in elderly patients remain unclear.
Methods
In this multicentre, prospective study, elderly patients receiving linezolid at four tertiary hospitals in Beijing between May 2021 and December 2022 were included. Linezolid concentrations and haematological toxicity were monitored dynamically. Risk factors for linezolid overexposure and moderate-to-severe linezolid-induced thrombocytopenia (M/S LIT) were analysed, and a predictive model of M/S LIT was developed.
Results
A total of 860 linezolid concentrations were measured in 313 patients. The median trough concentrations of linezolid were 24.4 (15.3, 35.8) mg/L at 36–72 h and 26.1 (17.0, 38.1) mg/L at 5–10 days (P = 0.132). Severe linezolid exposure was independently associated with age, estimated glomerular filtration rate (eGFR) and the worst SOFA score (SOFA1), and we further recommended dose regimens for elderly patients based on these findings. The incidences of linezolid-induced thrombocytopenia(LIT) and M/S LIT were 73.5% and 47.6%, respectively. M/S LIT was independently correlated with treatment duration, average trough concentration (TDMa), baseline platelet count, eGFR and baseline SOFA score (SOFA0). The developed nomogram predicted M/S LIT with an area under the curve of 0.767 (95% CI 0.715–0.820), a sensitivity of 71.1% and a specificity of 73.2%.
Conclusions
Linezolid trough concentrations increased dramatically in the elderly, by about 10 mg/L in patients aged 65–80 years, followed by a further increase of 10 mg/L for every 10 years of age. Therapeutic drug monitoring is recommended in elderly patients receiving linezolid. The developed nomogram may predict M/S LIT and guide dosage adjustments of linezolid. Clinical trial registration number: ChiCTR2100045707
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.
- Chinese PLA Medical School, Beijing 100853, China.
- Department of Pulmonary and Critical Care Medicine, The Fourth Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
- BGI Genomics Co., Ltd, Shenzhen 518083, China.
- Department of Pulmonary and Critical Care Medicine, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
- College of Pulmonary and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
ORCID-Profile: Hongxia Li
Förderung
- National Key Research and Development Program of China
- National Clinical Research Center Projects for Geriatric Diseases
- Special Project for Military Healthcare Scientific Research
Zitieren
APA
Liu, T., Yuan, Y., Wang, C., Wu, J., Wang, Y., Na, P., Chen, X., Rao, W., Zhao, J., Wang, D., Wang, H., Duan, Z., Xie, F., Fang, X., Xie, L., & Li, H. (2024). Therapeutic drug monitoring of linezolid and exploring optimal regimens and a toxicity-related nomogram in elderly patients: a multicentre, prospective, non-interventional study. Journal of Antimicrobial Chemotherapy, 79(8), 1938-1950. https://doi.org/10.1093/jac/dkae188
Vancouver
Liu T, Yuan Y, Wang C, Wu J, Wang Y, Na P, et al. Therapeutic drug monitoring of linezolid and exploring optimal regimens and a toxicity-related nomogram in elderly patients: a multicentre, prospective, non-interventional study. Journal of Antimicrobial Chemotherapy. 2024;79(8):1938-1950. doi:10.1093/jac/dkae188
BibTeX
@article{Liu2024,
author = {Liu, Tingting and Yuan, Yaping and Wang, Chao and Wu, Jionghe and Wang, Yajuan and Na, Peng and Chen, Xiaomin and Rao, Weiqiao and Zhao, Jing and Wang, Dan and Wang, Haiyan and Duan, Zhimei and Xie, Fei and Fang, Xiangqun and Xie, Lixin and Li, Hongxia},
title = {Therapeutic drug monitoring of linezolid and exploring optimal regimens and a toxicity-related nomogram in elderly patients: a multicentre, prospective, non-interventional study},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {8},
pages = {1938--1950},
doi = {10.1093/jac/dkae188}
}
EUVIMED